Literature DB >> 12887855

[Liver failure due to mushroom poisoning: clinical course and new treatment perspectives].

M V Catalina1, O Núñez, A Ponferrada, L Menchén, A Matilla, G Clemente, R Bañares.   

Abstract

Mushroom poisoning, mainly due to the Amanita genus, is an infrequent cause of liver failure in our environment. However, because of its high morbidity and mortality, it constitutes a medical emergency. The characteristic initial symptoms of vomiting, abdominal pain, and diarrhea are nonspecific and may be confused with gastroenteritis. If correct and early treatment is not given, renal and hepatic failure can develop, sometimes requiring liver transplantation. We present three cases of mushroom poisoning, which presented a different clinical course ranging from complete recovery with traditional medical treatment to severe acute liver failure requiring transplantation in one patient and albumin dialysis (molecular absorbent recycling system [MARS]) in another with favorable outcome. Although controlled clinical studies of the treatment of mushroom poisoning are lacking, recommendations based on the experience of various authors have been established. Penicillin G and silymarin seem to be useful. The development of new techniques of extracorporeal detoxification, mainly MARS, may represent an important support system in the treatment of these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12887855     DOI: 10.1016/s0210-5705(03)70383-5

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  2 in total

1.  Mushroom poisoning.

Authors:  M Erguven; O Yilmaz; M Deveci; N Aksu; F Dursun; M Pelit; N Cebeci
Journal:  Indian J Pediatr       Date:  2007-09       Impact factor: 1.967

2.  Effect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen.

Authors:  Hamid Emami; Ali Asghar Shakeri; Ali Akhavan; Daryoush Shahbazi-Gahrouei; Pouya Akbari
Journal:  J Res Med Sci       Date:  2018-12-28       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.